Related Experiment Videos
Treatment of refractory leukemia with high-dose cytosine arabinoside
Insights
High-dose cytosine arabinoside therapy showed promising results for patients with refractory leukemia. This treatment led to significant remission rates and was generally well-tolerated, offering a potential option for difficult-to-treat cases.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Refractory acute nonlymphocytic leukemia and accelerated phase chronic myeloid leukemia present significant treatment challenges.
- Limited effective therapeutic options exist for patients with these advanced hematological malignancies.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose cytosine arabinoside in patients with refractory acute nonlymphocytic leukemia or accelerated phase chronic myeloid leukemia.
- To determine response rates, duration of remission, and adverse events associated with this treatment regimen.
Main Methods:
- Thirteen patients with refractory acute nonlymphocytic leukemia or accelerated phase chronic myeloid leukemia were enrolled.
- Cytosine arabinoside was administered at a high dose of 3 g/m2/day.
- Patient responses, remission durations, and side effects were closely monitored.
Main Results:
- Six out of 10 evaluable patients responded to the high-dose cytosine arabinoside therapy.
- Three patients achieved complete remission, with a mean duration of 18 weeks.
- Partial remission durations ranged from 5 to 11 weeks; treatment was well-tolerated with manageable side effects.
Conclusions:
- High-dose cytosine arabinoside is an effective treatment option for selected patients with refractory acute nonlymphocytic leukemia and accelerated phase chronic myeloid leukemia.
- The observed response rates and manageable toxicity profile suggest potential clinical utility in difficult-to-treat leukemia cases.
Abstract:
Thirteen patients with refractory acute nonlymphocytic leukemia or with accelerated phase of chronic myeloid leukemia have been treated with high dose of cytosine arabinoside (Alcysten, Spofa). The drug was administered in doses of 3 g/m2/day. Six of 10 evaluable patients responded to the therapy. The mean duration of complete remission, achieved in 3 patients, was 18 weeks. The duration of partial remission ranged from 5 to 11 weeks. The treatment was well tolerated. Apart from expected hematological toxicity, transitory nausea and vomiting were the most frequently encountered side effects.